

## EXHIBIT<sup>10</sup>

Year	Valency/ Serotypes	Carrier	Dosage of saccharide/ Protein: saccharide ratio	Reference
<b>Pfizer/Wyeth Pharmaceuticals</b>				
1994	Bivalent 6A and 23F, OS and CPS and with or without linker	CRM197	2 and 10 µg of each serotype	Steinhoff, M.C. et al. (1994) A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. <i>Pediatr. Infect. Dis. J.</i> Vol. 13(5) pp 368-372.
1995	Pentavalent 6B, 14, 18C, 19 and 23F	CRM197	10 µg of each serotypes	Chiu, S.S. et al. (1995) Safety and immunogenicity of a pentavalent pneumococcal conjugate vaccine (PCV) in healthy toddlers. Presented at the 35 <sup>th</sup> Inter= Conf. Antimicrob. Agents and Chemotherapy, San Francisco Abstr G71 P 171.
	Pentavalent 6B, 14, 18C, 19F and 23F	CRM197	0.5, 2 and 5 µg of each serotype	Dauvin, R.S. et al. (1995) Immunogenicity of <i>S. pneumoniae</i> oligo- and polysaccharide-CRM197 conjugate vaccines in healthy US infants. Presented at the 35 <sup>th</sup> Interse Conf. Antimicrob. Agents and Chemotherapy, San Francisco Abstr G65 page 170.
1996	Bivalent 6A and 23F	CRM197	2 and 10µg of each serotype	O'Brien, K.L. et al. (1996) Immunologic priming of young children by pneumococcal glycoprotein conjugate but not polysaccharide vaccines. <i>Pediatr. Infect. Dis. J.</i> Vol. 15(5) pp 425-430.
	Pentavalent 6B, 14, 18C, 19F and 23F together with Tetramune	CRM197	10 µg of each serotype Ratio 1:3:1, overall ratio 2:1	Ahnman, H. et al. (1996) Pentavalent pneumococcal oligosaccharide conjugate vaccine PreCRM is well-tolerated and able to induce an antibody response in infants. The Pediatric Infectious Disease Journal. Vol. 15(2) pp 134-139.
	Hepatavalent 4, 6B, 9V, 14, 18C, 19F, 23F and 4 µg of serotype 6B 23F <sup>11</sup>	CRM197	2 µg of serotypes 4, 9V, 14, 18C, 19F, 23F and 4 µg of serotype 6B	Rennels, M.B. et al. (1996) Abstract from <i>Immunogenicity and Safety of 7-Tivalent Pneumococcal-CRM197 Conjugate Vaccine. Pediatric Research</i> , Vol. 39(4) part 2 p 183A. Abstr 1082.

<sup>10</sup> Note: In this table only the name of the current company is given. Wyeth Pharmaceuticals, recently purchased by Pfizer, was formerly Pasteur Merieux and Comnaught Laboratories.

<sup>11</sup> Approved and commercialized under the trademark Prevnar®.

Year	Vaccine/ Serotypes	Carrier	Dosage of saccharide/ Protein:	Reference
1997	Pentavalent 6B, 14, 18C, 19F and 23F	CRM197	10 µg of each serotype Ratio 0.5:1:1	Shelly, M.A. et al. (1997) <i>Comparison of pneumococcal polysaccharide and CRM197 conjugated pneumococcal oligosaccharide vaccines in young and elderly adults infection &amp; immunity</i> Vol. 65(1) pp 242-247.
1994	Monovalent 19F	DT	10 µg of each serotype	<i>Sanofi Pasteur</i>
	Tetravalent 6B, 14, 19F and 23F	DT or TT	10 µg of each serotype	Kennedy, D. et al. (1994) <i>Immunologic response of 12-18 months old children to licensed pneumococcal polysaccharide vaccine (PS) primed with Streptococcus pneumoniae 19F conjugate vaccine (CV)</i> . Presented at the 34 <sup>th</sup> Intersc. Conf. Antimicrob. Agents and Chemotherapy Orlando Abstr. G88 p 236.
	Tetravalent 6B, 14, 19F and 23F	T1	1, 3 and 10 µg of each serotype	Nieminen, T. et al. (1994) <i>Mucosal and serum immune response to tetravalent pneumococcal (Spn) conjugate vaccines (SpnD and SpnT) In adults</i> . Presented at the 34 <sup>th</sup> Intersc. Conf. Antimicrob. Agents and Chemotherapy Abstr. G89 p 236.
1995	-	-	-	Porter, H. et al. (1994) <i>Serum antibody response to a tetravalent pneumococcal tetanus toxoid conjugate vaccine in adult volunteers</i> . Presented at the 34 <sup>th</sup> Intersc. Conf. Antimicrob. Agents and Chemotherapy Abstr. GP1 p 236.
1996	Octavalent 3, 4, 6B, 9V, 14, 18C, 19F and 23F 3, 4, 6B, 9V, 14, 18C, 19F and 23F	TT DT	1 µg of each serotype 3 µg of each serotype	Ahnman, H. et al. (1996) <i>Immunogenicity of octavalent pneumococcal conjugate vaccines in Finnish infants</i> . ICAAC Abstract G40, page 150.
1994	Monovalent 14	OMpc	0.5, 1, 2.5 and 5 µg of each serotype	<i>Merck Sharp &amp; Dohm</i>
	Hepavalent 4, 6B, 9V, 14, 18C, 19F and 23F	OMpc	1 µg of serotypes 14, 18C, 19F, 23F, 4, 9V and 2.5 µg of serotype 6B	Keyserling, H. et al. (1994) <i>Immunogenicity of type 14 conjugate vaccine in infants</i> . Presented at the annual meeting of the American Pediatric Society/Society for Pediatric Research Seattle WA. Abstract 1087, p 84A.
				Kennedy, D. et al. (1994) <i>Immunologic response to licensed pneumococcal polysaccharide vaccine (PS) In infants primed with heptavalent Streptococcus pneumoniae conjugated vaccine</i> . Presented at the 34 <sup>th</sup> Intersc. Conf. Antimicrob. Agents and Chemotherapy, Orlando Abstract S90 p 236.

Year	Valency/ Serotypes	Carrier	Dosage of saccharide/ Protein: saccharide ratio	Reference
1995	Tetavalent 6A, 14, 19F and 23F	OMFc	1 µg of each serotype Ratio: 5.9:9.1:1	Käyhty, H. et al. (1995) <i>Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children.</i> J. Infect. Diseases. Vol. 172 pp 1273-1278.
1996	Hepaivalent 4, 6B, 9V, 14, 18C, 19F and 23F	OMFc	1 µg of serotypes 4, 14, 18C and 23F, 1.5 µg of serotype 9V, 2 µg of serotype 19F and 3.5 µg of serotype 6B Ratio: 7.8:1 (1.1µg PS and 85 PP OMPc)	Dagan, Ron et al. (1996) <i>Reduction of Nasopharyngeal Carriage of Pneumococci during the Second Year of Life by a Hepaivalent Conjugate Pneumococcal Vaccine.</i> J. Infect. Diseases Vol. 174 pp 1271-1278.
1997	Hepaivalent 4, 6B, 9V, 14, 18C, 19F and 23F	OMFc	In Lot A - total polysaccharide - 17.6 µg and total OMPc - 12.3 µg In Lot B total polysaccharide - 16.1 µg and total OMPc - 14.0 µg	Greenberg D.P. et al. (1997) <i>Factors Influencing the immunogenicity of a pneumococcal conjugate vaccine in infants.</i> Pediatr. Res. Vol. 41 p121 abstr 709.